BTHE - Boston Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0081
0.0000 (0.00%)
At close: 12:07PM EST
Stock chart is not supported by your current browser
Previous Close0.0081
Open0.0081
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0081 - 0.0081
52 Week Range0.0081 - 0.0500
Volume1,000
Avg. Volume45,189
Market Cap900,161
Beta (3Y Monthly)-0.54
PE Ratio (TTM)N/A
EPS (TTM)-0.0180
Earnings DateMar 25, 2016 - Mar 29, 2016
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.12
  • GlobeNewswire

    Boston Therapeutics Ph 2 Study Achieves Full Enrollment

    Boston Therapeutics (BTHE) is again pleased to announce full enrollment of the BTI320 Ph 2 double-blind, placebo-controlled, multicenter trial. With the recent inclusion of Miami Dade Medical Research Institute in June and IOWA Diabetes in Feb, recruitment of patients reached full enrollment on Aug 1, 2019(n=65).

  • GlobeNewswire

    Boston Therapeutics Announces Official Sales and Marketing Launch of Sugardown® in Asia

    Boston Therapeutics Inc. (the “Company” or “BTI”) (BTHE), an innovator in the design, development and commercialization of novel therapeutics as an adjunct therapy for diabetes, launches the initial sales and marketing of cross border products in China via one of the largest e-commerce platform: Tao Bao. Newly manufactured Sugardown® chewable tablets have been received in China in Jan 2019 to support the launching of product by an elite e-marketing group (JD Jin Long) in China. A total of 5,000 units have been allocated for this initial sales launch.

  • GlobeNewswire

    Boston Therapeutics Announces Marketing of Sugardown® in Asia

    LAWRENCE, Mass., Dec. 13, 2018 -- Boston Therapeutics, Inc. (the “Company” or “BTI”) (OTCQB: BTHE), an innovator in the design, development and commercialization of novel.

  • GlobeNewswire

    Boston Therapeutics Announces Initiation of Sales of Sugardown® in Asia

    Boston Therapeutics, Inc. (the “Company” or “BTI”) (BTHE), an innovator in the design, development and commercialization of novel therapeutics as an adjunct therapy for diabetes, launches an initial sale of product in Myanmar and test market in China. Newly manufactured Sugardown® chewable tablets have been received in China and are due for shipment and sale to China Mainland in the next two weeks. This may be a substantial contribution of up to $310,000 to support the Company from its Asian Partner.